Skip to content

Comparision of autologous Growth Factor Concentrate injection versus Platelet Rich Plasma injection in patients of Androgenic Alopecia receiving topical minoxidil

Efficacy of autologous Growth Factor Concentrate injection and Platelet Rich Plasma injection in patients of Androgenic Alopecia receiving topical minoxidil: A randomized control trial - NIL

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073394
Enrollment
44
Registered
2024-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: GROWTH FACTOR CONCENTRATE INJECTIONS: AUTOLOGOUS GROWTH FACTOR CONCENTRATE EXTRACTED USING CENTRIFUGATOR AND INJECTED IN THE SCALP AS INTRAEPIDERMAL INJECTIONS ONCE EVERY MONTH FOR 3 MO

Sponsors

Shini Choubey
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. AGA patient: Hamilton and Norwood classification grade: II– IV in male and Ludwig classification grade – I and II female 2. Both male and female between 21-45 years of age. 3. Androgenic Alopecia patients who have not received any other systemic or topical treatment.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Pregnant or lactating females 2. Patients with history of any existing scalp skin diseases (seborrheic dermatitis and scalp psoriasis), infections 3. Severe systemic illness (as uncontrolled DM or hypertension, liver or renal diseases) 4. Immunocompromised patients 5. Alopecia caused by other factors such as telogen effluvium, alopecia areata, or scarring alopecia. 6. Patients who are positive for HIV/ HBsAg /HCV/ VDRL.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy by comparing the final terminal and vellus hair ratio of both the groups.Timepoint: Baseline and 3rd month.

Secondary

MeasureTime frame
PATIENT SATISFACTION SCORE PAIN GRADATIONTimepoint: END OF 3 MONTHS

Countries

India

Contacts

Public ContactShini Choubey

Kalinga Institute of Medical Sciences

laxman.derm@gmail.com8108306532

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026